Transdermal Delivery Solutions Subsidiary, Hormone Replacement Technologies, Receives FDA Approval to Begin Pivotal Clinical Trials of Testagen® TDS for the Treatment of Low Testosterone

Published: Aug 22, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PALM BEACH GARDENS, Fla.--(BUSINESS WIRE)--Transdermal Delivery Solutions Corporation (TDSC) announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application submitted by its subsidiary, Hormone Replacement Technologies. Under the IND, Hormone Replacement Technologies will conduct several clinical trials of Testagen® TDS for the treatment of low testosterone in men, including Phase I and Phase II dosing studies, Phase II study investigating transference, and a Phase III comparative analysis.

Help employers find you! Check out all the jobs and post your resume.

Back to news